Oncostatin M (OSM), an interleukin-6 type cytokine, acts via the gp130 signaling receptor to inhibit proliferation and induce dierentiation of breast cancer cells. EGF, a mitogen for breast cells, signals via EGFR/ ErbB tyrosine kinase receptors which are implicated in breast cancer pathogenesis. Here we show paradoxically that EGF enhanced the OSM-induced inhibition of proliferation and induction of cellular dierentiation in both estrogen receptor positive and negative breast cancer cells. This functional synergism was also seen with heregulin but not SCF, PDGF or IGF-1, indicating that it was speci®c to EGF-related growth factors. Immunoprecipitation experiments revealed that gp130 was constitutively associated with ErbB-2 and ErbB-3. There was a similar association between the OSMRb and ErbB-2. Furthermore, EGF unexpectedly induced tyrosine phosphorylation of gp130. We show that OSM induced phosphorylation of STAT3. Both OSM and EGF activated the p42/44 MAP kinases, but while the MEK inhibitor, PD98059, ablated the OSM-induced inhibition, it only partially ablated the inhibitory eects of OSM plus EGF. Thus, we have demonstrated that the receptors and signalling pathways of two apparently unrelated growth factors were intimately linked, resulting in an unexpected biological eect. This provides a new mechanism for generating signalling diversity and has potential clinical implications in breast cancer.
Introduction
Oncostatin M (OSM) is a pleiotropic cytokine, ®rst identi®ed by its ability to inhibit growth of several cancer cell lines (Horn et al., 1990; Zarling et al., 1986) . We have previously shown that OSM inhibits the proliferation of estrogen receptor (ER) positive and negative breast cancer cell lines (Douglas et al., 1997 (Douglas et al., , 1998 . This inhibition is associated with decreased clonogenicity, cell cycle suppression, alterations in cellular morphology and a number of other changes, all consistent with induction of dierentiation in these cells (Douglas et al., 1998) .
OSM is a member of the interleukin-6 (IL-6) type cytokine family which includes leukemia inhibitory factor (LIF), interleukin-11 (IL-11), cardiotrophin 1 (CT-1) and ciliary neurotrophic factor (CNTF). These cytokines mediate a number of overlapping biological activities which is in part explained by the sharing of the signal-transducing receptor subunit, gp130 (Gearing et al., 1992; Hibi et al., 1996; Taga, 1996) . In addition, a number of these cytokines also share the LIF speci®c receptor subunit (LIFRb). The receptor complex utilized by OSM is unique in the IL-6 cytokine family in that OSM is the only member to bind gp130 directly, with low anity (Gearing et al., 1992) . Subsequent to OSM binding, gp130 forms a high anity receptor complex with either the LIFRb or the OSM-speci®c receptor (OSMRb) to form the type I and II OSM receptors, respectively (Auguste et al., 1997; Grant and Begley, 1999; Mosley et al., 1996) .
Upon OSM binding the dimerization of receptor subunits initiates activation of intracellular signalling pathways. The JAK/STAT pathway is the most characterized pathway downstream of gp130. In response to IL-6 type cytokines, JAK1, and to a lesser extent, JAK2 and Tyk2, which associate constitutively with the cytoplasmic domains of gp130, LIFRb or OSMRb, become activated. JAKs induce phosphorylation of conserved tyrosine residues on each receptor subunit, which act as docking sites for STAT molecules (Auguste et al., 1997; Guschin et al., 1995; Stahl et al., 1994). STATs are tyrosine phosphorylated, dimerise and translocate to the nucleus where they regulate transcription of target genes. STATs 1, 3 and 5 can be activated in response to IL-6 type cytokines, however activation of STAT3 has been shown to be critical for a number of biological eects including growth inhibition and dierentiation-induction of M1 myeloid leukemic cells, inhibition of A375 melanoma cell proliferation and enhanced proliferation and survival of BAF3 cells (Fukada et al., 1998; Kortylewski et al., 1999; Nakajima et al., 1996) .
In addition to the JAK-STAT pathway, IL-6 family cytokines signal via the mitogen activated protein kinase (MAPK) pathway. In adipocytes, MAPK activation is critical for LIF induced dierentiation, in Kaposi's Sarcoma cells, OSM and IL-6 induced growth is mediated via ERK1/2 (p42/44 MAPK) and activation of this pathway is important for OSM induced growth inhibition of glioma cells (Aubert et al., 1999; Halfter et al., 1999; Murakami-Mori et al., 1999) .
EGF is a polypeptide growth factor implicated in the pathogenesis of breast cancer. EGF is mitogenic for breast epithelial and cancer cells (Dickson and Lippman, 1988; Fitzpatrick et al., 1984b; Osborne et al., 1980) . The EGF Receptor (EGFR/ErbB-1) is a receptor tyrosine kinase overexpressed in about 50% of breast tumours which is associated with aggressive disease and poor prognosis and correlates inversely with ER expression (Davidson et al., 1987; Fitzpatrick et al., 1984a; Gullick, 1991; Harris et al., 1989) .
The EGF receptor/ErbB family consists of four members, EGFR/ErbB-1, -2, -3 and -4. In addition to EGFR/ErbB-1, ErbB-2 (HER2/neu) is overexpressed in a number of breast tumours and many other types of cancer. ErbB-2 is considered to be the most oncogenic of all ErbB family members, despite being an orphan receptor with no characterized ligand (Klapper et al., 2000) . Although EGF can signal via a dimer of the EGFR with any ErbB family member, ErbB-2 is the preferred heterodimerization partner of all activated ErbB receptors (Graus-Porta et al., 1997) . In breast cancer patients, overexpression of ErbB-2 correlates with aggressive disease and shorter disease free survival. The third member, ErbB-3, contains a non-functional kinase and can only signal as a heterodimer. Correlation between ErbB-3 expression in breast cancer and prognosis has not been shown (Klapper et al., 2000) . Activation of ErbB receptors leads to signalling via a number of molecules including PLCg, PI3 kinase, Shc, Grb-2 and Src, leading to activation of the MAPK pathway (Tzahar and Yarden, 1998) . More recently, targeting the ErbB-2 receptor using the humanized monoclonal antibody trastuzumab (Herceptin) has shown promising results in clinical trials in patients with metastatic breast cancer (Baselga, 2000) .
In this study we have examined the eects of OSM in combination with EGF on breast cancer cell proliferation, morphology, gene expression and phenotypic changes of dierentiation. In addition we have examined the signalling pathways of OSM and EGF in breast cancer cells and identi®ed interactions between gp130, the OSMRb and ErbB receptors.
Results
The action of OSM in combination with EGF on breast cancer cells EGF has been recognized as a mitogen for breast cancer cells, in part because of its documented ability to overcome the inhibitory eects of anti-estrogens, progestins and dexamethasone (Koga and Sutherland, 1987; Rao et al., 1987; Sarup et al., 1988) . To address whether EGF could also overcome the inhibitory eect of OSM, we examined the eects of combination of these growth factors on proliferation of MCF-7 cells. In control cultures, cell number increased in an exponential manner ( Figure 1a ). Treatment of MCF-7 cells was performed deliberately with a submaximal concentration of OSM (10 ng/ml) and resulted in an inhibition of proliferation, evident after 2 days ( Figure  1a ). In these conditions, in the presence of serum, as expected EGF did not alter cell growth signi®cantly from control ( Figure 1a) . Unexpectedly, the combination of OSM plus EGF resulted in more profound inhibition of proliferation than seen with OSM alone (Figure 1a ; P50.001, OSM vs OSM plus EGF). In 10 independent experiments a mean of 48% inhibition at day 7 was seen in response to OSM (Figure 1b ; P50.001, OSM versus control), while a mean 80% inhibition was seen in response to OSM plus EGF (P50.001, OSM vs OSM plus EGF) and this inhibition of proliferation was further enhanced when EGF was combined with a higher concentration of OSM (100 ng/ml) (data not shown). To con®rm the actions of OSM in combination with EGF, an additional cell line, MDA-MB-231, was examined. The action of EGF to signi®cantly enhance OSMinduced inhibition was also observed using this ER negative cell line (OSM, 36.4% inhibition vs OSM plus EGF, 61.7% inhibition, P50.001) (Figure 1c ). Importantly, MDA-MB-231 cells express high levels of the EGFR whilst ER positive MCF-7 cells express low levels of EGFR. In serum free cultures, the mitogenic eects of EGF were evident (cell number 16% above control) (Figure 1d ). In these experiments, the enhanced eect of OSM plus EGF was also observed (OSM, 22% inhibition vs OSM plus EGF, 46% inhibition, P50.001 (Figure 1d ). EGF also increased the clonogenicity of MCF-7 cells cultured in semi-solid agar (cell number 20% above control) (not shown). Consistent with experiments described above, the reduced proliferation in OSM plus EGF cultures was also associated with decreased clonogenicity of breast cancer cells (OSM, 60% inhibition vs OSM plus EGF, 71% inhibition) (OSM vs OSM plus EGF, P50.01, n=7 experiments in quadruplicate) and there was no evidence that cells became refractory to on-going treatment with growth factors (data not shown).
EGF acted in concert with OSM to decrease the proportion of MDA-MB-231 cells in S phase of the cell cycle with a proportional increase of cells in the G0/G1 phase of the cycle (Figure 1e,f) . This action of OSM in combination with EGF was greater than the eect seen with OSM alone. Similar results were seen in MCF-7 cells.
Thus, the inhibition seen with OSM treatment was enhanced by EGF in several cell culture systems. This included when treatment with EGF apparently had a modest inhibitory action (Figure 1b) , when EGF had no eect on cell proliferation (Figure 1c) when EGF acted as a mitogen (Figure 1d ) and in ER positive and ER negative cells.
The enhanced anti-proliferative eects of OSM in combination with EGF were also observed when EGF was combined with IL-6 or LIF. We have previously reported that IL-6 and LIF modestly inhibited the proliferation of MCF-7 cells (Douglas et al., 1997) . In the presence of EGF, the inhibitory eects of these cytokines were enhanced (IL-6, 9% inhibition; IL-6 plus EGF, 30% inhibition; LIF, 11% inhibition; LIF plus EGF, 51% inhibition, when cell number was compared to control, n=3 independent experiments, each performed in triplicate). These results suggest that the interaction with EGF may apply more generally to cytokines which utilize gp130 as a receptor subunit. However, given that these changes were most striking with OSM, all further studies were performed with OSM.
OSM-induced differentiation of breast cancer cells is enhanced by OSM plus EGF
Northern analysis was performed to determine the eect of the growth factor combination on gene expression in MCF-7 cells. Expression of c-fos increased in response to both OSM and EGF alone. After 30 min exposure to OSM or EGF, densitometric analysis revealed that c-fos levels were elevated approximately sevenfold and fourfold, respectively (Figure 2a ). The combination of OSM plus EGF resulted in a further modest increase in c-fos expression (14-fold above control by densitometric analysis). Alterations in expression were transient with no further changes after 2 h. Early upregulation of cmyc was also observed in response to both growth factors. In cells exposed to either OSM or EGF, levels increased approximately 3.5-fold and twofold above that of control, respectively. With OSM plus EGF, there was a further modest increase in c-myc expression (sevenfold greater than in control cells after 2 h). Again, alterations in expression were transient, returning to baseline within 8 h and remained unchanged for 48 h. We subsequently performed Northern analysis to examine the eect of growth factor treatment on expression of ER and EGFR. mRNA for EGFR was increased in response to OSM, EGF and OSM plus EGF (Figure 2b ). After treatment with OSM, the levels of EGFR mRNA were elevated between 4 ± 12 h. At 4 h, EGFR expression exceeded control by approximately ®vefold and remained at this level for 12 h (data not shown). After this, EGFR mRNA remained approximately twofold elevated compared with control. In cells treated with OSM plus EGF the increase in EGFR mRNA was evident after 8 h treatment. At 8 h mRNA levels exceeded control by approximately ®vefold, and this was increased to approximately 10-fold above control by 48 h. The magnitude of change in EGFR mRNA in OSM plus EGF treated cells was similar to that seen with EGF alone.
Expression of ER mRNA was suppressed by OSM treatment and was further decreased by treatment with OSM plus EGF (threefold decrease in response to OSM compared to 25-fold in response to OSM+EGF as assessed by densitometry) (Figure 2b ). These changes were observed after 8 h. The reduction of expression of ER was evident at 48 h, and remained sustained for at least 6 days (data not shown). Treatment of cells with EGF had no signi®cant eect on ER mRNA expression. The decrease in ER was also con®rmed using immunohistochemical staining ( In addition to eects on ER expression and cell growth, alterations in cell morphology were observed. Following exposure to OSM cells were enlarged with apparent loss of cell-cell adhesion (Figure 2d ). These changes were more dramatic following treatment with OSM plus EGF (Figure 2e ). The cells were further enlarged, with more abundant cytoplasm and marked cytoplasmic vacuolation. There was considerable variation in nuclear size, and cytoplasmic processes were particularly prominent. Perinuclear lucency and pale cytoplasmic inclusions were observed in many cells.
Associated with these morphological changes, there was accumulation of neutral lipid droplets in the cytoplasm of these cells, a characteristic of breast cell dierentiation. This was detected using the lipid staining dye, Oil-Red-O ( These results demonstrate that EGF, rather than overcoming OSM-induced inhibition, caused a more profound inhibition of proliferation and clonogenicity along with enhanced cellular dierentiation with more dramatic morphological changes, increased EMA expression and reduced ER expression. Thus the interaction between OSM and EGF contrasts with the previously documented ability of EGF to overcome similar inhibitory eects of anti-estrogens, progestins and dexamethasone.
The interaction with OSM is specific to EGF-related growth factors
To address the speci®city of the interaction between OSM and EGF, experiments were performed to determine whether the eects of OSM could be enhanced when combined with other growth factors which utilize tyrosine kinase receptors.
Heregulin (HRG) is an EGF related growth factor which has multiple isoforms (HRGb2 used in these studies) and is a ligand for ErbB-3 and ErbB-4 and activates ErbB-2 indirectly (Tzahar et al., 1994) . HRG is also a potent mitogen for MCF-7 cells and several other breast cancer cell lines (Fiddes et al., 1995) although, in this experiment the mitogenic eects were not observed. After 7 days in culture, the inhibition of proliferation in response to OSM plus HRG was comparable to that seen with OSM plus EGF, and was signi®cantly more marked than seen with OSM alone (P50.01, OSM compared to OSM plus HRG) ( Figure  3a ). In addition, after exposure to OSM plus HRG there was a similar suppression of ER expression as with OSM plus EGF treatment with only 10% of cells expressing the ER (data not shown). Alterations in cell morphology were also enhanced when cells were treated with OSM in combination with HRG as compared to treatment with OSM alone (data not shown). This suggested that the enhancement of the eects of OSM was not restricted to EGF but was also mediated by other growth factors that utilize the EGF receptor/ErbB family of receptors.
Insulin-like growth factor-I (IGF-I) is a potent mitogen for some breast cancer cell lines (including MCF-7 cells) and has been implicated in breast cancer pathogenesis (De Leon et al., 1992) . Platelet derived growth factor (PDGF) and stem cell factor (SCF) utilize tyrosine kinase growth factor receptors belong- Results represent means and standard deviations from four independent experiments for each growth factor combination, with each experiment performed in triplicate ing to the same class. PDGF and its receptor, and SCF and its receptor c-kit, are expressed by MCF-7 cells, have been implicated in growth deregulation of breast tumours and correlate with poor prognosis (Hines et al., 1995; Seymour and Bezwoda, 1994) . The signalling pathways downstream of IGF-1, PDGF and SCF are well characterized (reviewed by Bornfeldt et al., 1995; Taylor and Metcalfe, 2000; Valentis and Baserga, 2001) . After 7 days culture, treatment with IGF-1, PDGF or SCF alone had no signi®cant eect on MCF-7 cell proliferation (Figure 3b ± d) . As before, treatment with a submaximal concentration of OSM inhibited cell proliferation by approximately 40%. However, in contrast to the results with EGF and HRG, in four separate experiments, the inhibitory eects of OSM were not in¯uenced by combination with IGF-1 (Figure 3b ), PDGF (Figure 3c ) or SCF (Figure 3d ). These results suggested that interaction between gp130 and the EGF/ErbB family of growth factors and receptors was speci®c, and was not seen with other growth factors utilizing members of the tyrosine kinase receptor family.
Association of OSM receptor components with ErbB-2 and ErbB-3 in breast cancer cells
The ErbB-2 oncoprotein has been demonstrated to form a complex with gp130 in prostate carcinoma cells, in an IL-6 dependant manner (Qiu et al., 1998) . We therefore sought to determine whether a similar association of gp130 with EGF receptor family members was apparent in breast cancer cells treated with OSM and/or EGF. In MCF-7 cells, ErbB-2 was co-immunoprecipitated with gp130 ( Figure 4a ). This co-immunoprecipitation was evident in untreated MCF-7 cells and in four separate experiments, the complex between gp130 and ErbB-2 was not altered by stimulation with OSM, EGF, or OSM plus EGF. The co-immunoprecipitation was independent of the antibodies used; it was detected when cell lysates were immunoprecipitated with four dierent anti-gp130 antibodies and Western blotted with two anti-ErbB-2 antibodies, and also in reverse where lysates were immunoprecipitated with anti-ErbB-2 and Western blots probed with anti-gp130 (Figure 4b ). Filters (Siegel et al., 1999) . All experiments were performed with negative controls of lysates immunoprecipitated with an irrelevant, isotype matched antibody (not shown) containing immunoprecipitated gp130 were stripped and re-probed with an anti-gp130 antibody to con®rm equivalent levels of protein in each lane (Figure 4a,b) . In addition, equal amounts of protein were immunoprecipitated with anti-ErbB-2 and blots probed with anti-ErbB-2 to con®rm equal expression levels of ErbB-2 protein in each lysate sample (Figure 4a) . In each experiment, equal amounts of lysate were immunoprecipitated with an irrelevant, isotype matched antibody, as a negative control (not shown). Lysates were also prepared using M1/UR21 cells, which were transfected with human gp130 (Hammacher et al., 1998) . These cells lack endogenous ErbB-2 and thus are an appropriate negative control. There was no evidence of co-immunoprecipitation of an ErbB-2 size protein with gp130 in M1/UR21 cells, thus providing further evidence for the speci®city of gp130 and ErbB-2 association in MCF-7 cells (Figure 4a ). These results implied that gp130 was constitutively associated with ErbB-2 in MCF-7 cells although the exact proportion of gp130 involved in this complex with ErbB-2 (and vice-versa) is unknown. Similar results showing a constitutive co-immunoprecipitation between gp130 and ErbB-2 were demonstrated in the ER negative MDA-MB-231 cell line (Figure 4c ). In this experiment, Western blots of gp130 immunoprecipitates were probed successively with anti-ErbB-2 and anti-gp130 to show the presence of both proteins on the same gel (Figure 4c) .
We also examined whether other members of the EGF receptor family were capable of forming a complex with gp130. Similar to the case with ErbB-2, in four independent experiments, ErbB-3 co-immunoprecipitated with gp130 in MCF-7 cells (Figure 4d ). This co-immunoprecipitation was also evident when lysates were immunoprecipitated with an anti-ErbB-3 antibody and probed with an anti-gp130 antibody (data not shown). Again, complex formation was not altered by stimulation of cells with OSM, EGF or OSM plus EGF. In this experiment, ®lters were also stripped and reprobed with anti-gp130 to con®rm equivalent loading and experiments were performed to con®rm equivalent expression of ErbB-3 protein in each sample (Figure 4d) . A similar association between gp130 and ErbB-3 was found in MDA-MB-231 cells. Thus, we conclude that both ErbB-2 and ErbB-3 were constitutively associated with gp130 in ER positive and ER negative breast cancer cells.
Interestingly, in contrast to the results with ErbB-2 and ErbB-3, the EGFR/ErbB-1 did not appear to associate with gp130. Initially we examined whether EGFR could form a complex with gp130 in the ER positive MCF-7 cell line. In view of the results with ErbB-2 and ErbB-3, we assumed the failure to demonstrate an interaction was the result of the low levels of EGFR expression in these cells. However, in subsequent experiments, we examined MDA-MB-231 cells, which express very high levels of the EGFR. Again, despite using several anti-EGFR antibodies, we were unable to demonstrate any association between gp130 and EGFR (data not shown). These results provide further support for the speci®city of interaction between gp130 and members of the ErbB family of tyrosine kinase receptors.
Experiments were performed to determine whether the OSM-speci®c receptor (OSMRb) was associated with ErbB-2. Similar to results seen with gp130 association with ErbB-2 and ErbB-3, we detected constitutive co-immunoprecipitation of the OSMRb with ErbB-2 in MCF-7 cells (Figure 4e ). The apparent increase in OSMRb co-immunoprecipitation with ErbB-2 in response to OSM plus EGF, compared to treatment with either growth factor alone, was not consistently observed in other experiments. Therefore, both gp130 and the OSMRb were constitutively associated with ErbB receptors, implicating this biochemical interaction in the mechanism of the functional interaction seen with OSM and EGF. The interaction between gp130 and ErbB-2 was also seen in HepG2 cells (Figure 4f ).
Induction of tyrosine phosphorylation of gp130 by EGF
In addition to examining the interaction between gp130 and EGF receptor family members we have also examined tyrosine phosphorylation of gp130, EGFR, ErbB-2 and ErbB-3 in MCF-7 and MDA-MB-231 cell lines. Similar results were found in both cell lines. As expected, treatment of cells with OSM induced tyrosine phosphorylation of gp130. Surprisingly, but consistent with the biological responses described above, treatment of cells with EGF also induced tyrosine phosphorylation of gp130 ( Figure  5a ). Tyrosine phosphorylation was evident within 5 min of growth factor treatment and gp130 remained phosphorylated for at least 2 h following treatment (not shown). There was no signi®cant dierence in gp130 tyrosine phosphorylation when cells were treated with OSM plus EGF, compared to treatment with either growth factor alone. Taken together, these results provide further evidence to suggest an interaction between the OSM and the EGF signalling pathways in breast cancer cells and suggest, for the ®rst time that EGF can induce signal transduction via gp130.
Both EGFR and ErbB-2 were rapidly tyrosine phosphorylated in response to EGF stimulation (Figure 5b,c) . To a lesser extent, ErbB-3 phosphorylation was induced by EGF (not shown). Results from four independent experiments suggested that there was no signi®cant dierence in tyrosine phosphorylation of EGFR and ErbB-2 when cells were treated with OSM plus EGF, compared to treatment with EGF alone. Tyrosine phosphorylation of EGFR and ErbB-2 was not detected in response to OSM treatment alone.
OSM and EGF-induced signal transduction in breast cancer cells
In addition to examining the phosphorylation of receptor components, we examined the activation of downstream signalling molecules. The JAK-STAT pathway of signal transduction has been demonstrated to be critical for eects induced by IL-6 type cytokines. In particular, STAT3 activation is required for IL-6 and OSM induced growth arrest and dierentiation in several cell types (Halfter et al., 1999; Kortylewski et al., 1999; Nakajima et al., 1996) . In addition, EGF has been demonstrated to induce tyrosine phosphorylation of STAT3 (Zhong et al., 1994) . In four separate experiments in MCF-7 cells, both OSM, and OSM plus EGF induced tyrosine phosphorylation of STAT3 in MCF-7 cells, evident within 5 min treatment ( Figure  6a ). STAT3 phosphorylation decreased after 60 min but returned after 2 h and was still evident 24 h after growth factor treatment (not shown). Similar results were found in MDA-MB-231 cells. Despite having been demonstrated in other systems, treatment of cells with EGF did not induce tyrosine phosphorylation of STAT3 in either cell line. Equal amounts of whole cell lysate were electrophoresed and Western blotted with anti-STAT3 to con®rm equivalent levels of protein in each lane. No signi®cant increase in tyrosine phosphorylation of either STAT1 or STAT5 was observed in either cell line stimulated with OSM, or EGF alone, and in combination (not shown).
In addition to the JAK-STAT pathway of signal transduction, the MAPK pathway is also involved in signalling by IL-6 type cytokines (Aubert et al., 1999; Halfter et al., 1999; Murakami-Mori et al., 1999) . To determine the signi®cance of the MAPK signalling pathway in breast cancer cells in response to OSM and EGF, we examined phosphorylation of p42/44 MAP kinases (ERK2 and 1 respectively). In response to EGF, p42 and p44 were phosphorylated within 5 min and remained activated for at least 2 h (Figure 6b ). This was similar when MCF-7 cells were treated with OSM plus EGF. Treatment with OSM alone also induced phosphorylation of p42/44, however the kinetics of activation were dierent to treatment with EGF, with maximum phosphorylation of p42/44 evident after 30 min (Figure 6b) . Similar results were seen in MDA-MB-231 cells. We also examined phosphorylation of the stress activated protein kinase, p38, and found no consistent activation by either OSM or EGF in MCF-7 or MDA-MB-231 cells (not shown). Thus, phosphorylation of p42/44 MAPK by both OSM and EGF represented activation of a common signalling pathway, although the dierent kinetics in activation raise the possibility that separate mechanisms are involved.
Given that the MAPK pathway was activated in response to OSM and EGF, we utilized a MAPK inhibitor to examine the role of this pathway in biological responses induced by OSM and EGF in MCF-7 cells. PD98059, the inhibitor used in these studies, inhibits MEK1 activation and thus prevents activation of the downstream p42/44 MAP kinases, which are activated by a number of growth factors. In these experiments, MCF-7 cells were cultured for 7 days in the presence of OSM or EGF, alone and in combination, with or without PD98059. In the absence of PD98059, treatment of MCF-7 cells with OSM resulted in a 48% inhibition of proliferation after 7 days treatment (Figure 6c ). Consistent with previous experiments, the combination of OSM with EGF resulted in an approximate 80% reduction in cell number. In four separate experiments, incubation of MCF-7 cells with increasing concentrations of PD98059, resulted in a concentration dependant inhibition of the eects of OSM on growth of MCF-7 cells (Figure 6c) . Interestingly, whilst the inhibitory eects of OSM were completely blocked by 10 mM PD98059, the eects of OSM plus EGF were only partially reversed, even when cells were exposed to 30 mM PD98059. We also examined the eects of the p38 inhibitor, SB203580, on the responses induced by OSM and EGF in MCF-7 cells (not shown). Consistent with phosphorylation experiments, p38 did not appear to be involved in the biological responses induced by OSM or EGF in breast cancer cells. Taken together, these results suggest that whilst the MAPK pathway is activated by OSM and EGF and may be critical for responses induced by treatment with these growth factors alone, additional signalling pathways must be involved when OSM and EGF are combined.
Discussion
The action of EGF to enhance the inhibitory eect of OSM was surprising. Previous studies have demonstrated that EGF stimulates the proliferation of breast cancer cell lines, including MCF-7 cells and cultures of primary mammary epithelium (Fitzpatrick et al., 1984b; Osborne et al., 1980) . In addition EGF has been documented to overcome the inhibitory or cytotoxic eects of several agents including dexamethasone, progestins, anti-estrogens and Tumour Necrosis Factor alpha (TNFa) on breast cancer cells (Homann et al., 1998; Koga and Sutherland, 1987; Rao et al., 1987; Sarup et al., 1988) . In contrast however, in the presence of OSM, we have demonstrated that EGF potentiated the inhibition of cell proliferation. EGF, also enhanced the induction of breast cancer cell dierentiation by OSM, with further suppression of ER, alterations in cellular morphology, altered lipid production and enhanced EMA expression. Although it is well recognized that some growth factors can both inhibit and promote proliferation, this usually occurs in a dierent cellular context. Thus, for example, OSM and other members of the IL-6 family of cytokines promote dierentiation with loss of proliferative potential in M1 myeloid leukemic cells, while they prevent dierentiation and promote self-generation in Embryonic Stem (ES) cells (Metcalf et al., 1988; Rose et al., 1994) . Such diering actions have not been as clearly documented for EGF and it is best characterized as a growth stimulus in many cell types. We are not aware of previous reports demonstrating that EGF can display both proliferative and anti-proliferative eects, particularly in the same cell line.
The enhancement of the OSM eect by EGF was also unexpected because, in contrast to our results, EGF has been demonstrated to attenuate IL-6 induced expression of hepatic acute phase proteins (Wang et al., 1999) . In prostate cancer cells, ErbB-2 was shown to be required for IL-6-induced signalling and cell proliferation (Qiu et al., 1998) . However, in that study there was no evidence for an enhanced or reduced biological eect as a consequence of an interaction between IL-6 and any EGF related growth factors. Here we showed that EGF acted to signi®cantly enhance the inhibitory eects seen with OSM. The eect of EGF to enhance the gp130-mediated action was speci®c: while also seen with HRG, it was not observed with other growth factors that utilize tyrosine kinase receptors.
One potential explanation for this interaction between OSM and EGF was provided by the coimmunoprecipitation of gp130 with ErbB-2 and ErbB-3. This association occurred in the absence of ligand and was evident in both ER positive and negative breast cells. In addition an interaction in the absence of ligand was also demonstrated between the OSMRb and ErbB-2. We were unable to demonstrate an association between gp130 and the EGFR, even in the presence of EGF, and using multiple dierent antibodies. In light of our other results, this failure was unexpected, however this result is consistent with the report that IL-6 could induce a complex formation between gp130 and ErbB-2 and ErbB-3 but not EGFR (Qiu et al., 1998) . While a failure to demonstrate an interaction between gp130 and EGFR on MCF-7 cells could be attributed to the low number of EGFR receptors on those cells, this explanation does not apply to the MDA-MB-231 cells. Instead this result implies a level of speci®city in terms of interaction between EGF receptor family members and gp130. In contrast, to the IL-6 dependent interaction between gp130 and ErbB-2 in prostate cancer the interaction we observed occurred in a ligand-independent manner and was associated with a dramatic functional consequence (Qiu et al., 1998) . In view of the data presented here it is tempting to speculate whether some of the eects of the anti-ErbB2 antibody, Herceptin, might be mediated via an eect on gp130, perhaps even mimicking an OSM eect on breast cells.
Whilst the constitutive association between gp130 and ErbB-2 and ErbB-3 implicates cross talk between these receptors, it does not provide any information about activation of downstream targets by OSM or EGF. Thus, a further explanation for the functional interaction between OSM and EGF was provided by our observation that EGF induces tyrosine phosphorylation of gp130. OSM and other IL-6 type cytokines have been clearly documented to induce phosphorylation of gp130, where activation is required for biological response Qiu et al., 1998; Taga, 1996) . In addition to IL-6 type cytokines, we have demonstrated for the ®rst time that EGF can also induce phosphorylation of gp130. This implies that EGF can activate intracellular signalling via gp130 as well as EGFR/ErbB complexes. Activation of JAK1 has been shown to be critical for gp130 mediated responses (Guschin et al., 1995) . EGF has also been previously demonstrated to activate JAK 1 and 2 (Olayioye et al., 1999) . In our case however, it is unclear whether gp130 activation by EGF is occurring via a JAK kinase, kinases such as PI3K, src kinases or via the associated ErbB-2 kinase. It is possible that the juxtaposition of an EGF-activated, functional ErbB-2 kinase may be sucient to induce gp130 tyrosine phosphorylation. The precise mechanism by which EGF induces phosphorylation of gp130 remains unclear but taken together, these ®ndings represent a novel mechanism by which a growth factor, EGF, and its tyrosine kinase receptor components can diversify intracellular signalling and ultimately, biological outcome by interacting with and activating a cytokine receptor, gp130.
The unique or modi®ed downstream intracellular signalling pathway(s) utilized as a result of the interaction between EGF and OSM is not clear. EGF has been demonstrated to induce phosphorylation of STAT3 in several cell types (Olayioye et al., 1999; Zhong et al., 1994) . However, despite the ability of EGF to induce phosphorylation of gp130 in our studies, this did not lead to tyrosine phosphorylation of STAT3 in MCF-7 or MDA-MB-231 cells. The activation of STAT3 in response to IL-6 cytokines is well characterized and in many cases, is critical for biological response (Kortylewski et al., 1999; Nakajima et al., 1996) . Therefore, as we expected, treatment of cells with OSM induced STAT3 phosphorylation, implying that STAT3 activation was also important for the biological response induced by OSM in breast cancer cells. STAT3 phosphorylation was not altered when cells were treated with OSM plus EGF, compared to treatment with OSM alone and we were not able to demonstrate activation of any other STAT family member by OSM or EGF. Thus, these results imply that STAT3 activation was an important mediator in the OSM signalling pathway but probably did not account for the eects of EGF or the unique eects of OSM in combination with EGF.
Treatment of cells with either OSM or EGF alone activated p42/44 MAP kinases, as has been documented previously in other systems (Halfter et al., 1999; Tzahar and Yarden, 1998) . This phosphorylation was also evident when cells were treated with the combination of OSM plus EGF. In MCF-7 cells, the MEK1 inhibitor, PD98059, was able to completely abolish the inhibition of proliferation induced by OSM in these cells indicating that MAPK activation was critical for OSM-induced inhibition of breast cancer cell proliferation. The signi®cance of STAT3 phosphorylation by OSM in terms of a biological outcome was therefore unclear. However, it has been shown that both MAPK and STAT3 activation are important for eects induced via gp130 signalling . In addition, there are several examples that implicate the MAPK pathway in proliferative responses induced by gp130 family cytokines and JAK/STAT activation in cellular dierentiation (Aubert et al., 1999; Halfter et al., 1999; Nakajima et al., 1996) . We speculate that in our case, whilst MAPK activation was important for OSM induced inhibition of proliferation, STAT3 activation may be critical for the changes in cell dierentiation status that we observed. Interestingly, incubation of MCF-7 cells with the inhibitor PD98059 only partially abrogated the eects of OSM plus EGF, even at considerably higher concentrations than was eective with OSM alone. This suggested that the combination of OSM plus EGF was able to activate intracellular signalling via both a MEK1-independent and a MEK1-dependent pathway.
Here, we have demonstrated, for the ®rst time, a unique functional and biochemical interaction between OSM and EGF and their receptors in breast cancer cells. We have demonstrated that gp130 and the OSMRb are constitutively associated with ErbB-2. In addition, the induction of tyrosine phosphorylation of gp130 by EGF and activation of common and divergent downstream signalling pathways implicate a novel cytokine/ growth factor cross-talk mechanism in breast cancer cells. This interaction is associated with a signi®cant biological outcome, with EGF, a classical breast cell mitogen, capable of enhancing the eects of the inhibitor, oncostatin M. Ultimately, given the clinical importance of the EGFR/ErbB receptor family in breast cancer, an understanding of these interactions may be of considerable clinical signi®cance.
Materials and methods

Breast cell lines
The origin of breast cell lines has been previously described (Douglas et al., 1997 (Douglas et al., , 1998 . The MCF-7 and MDA-MD-231 cell lines originated from an estrogen receptor (ER) positive and an ER negative breast cancer respectively. Cell lines were grown in monolayer in RPMI-1640 medium containing 10% (v/v) bovine calf serum (BCS) at 378C in a humidi®ed atmosphere, containing 10% CO 2 in air. Cell lines were passaged twice weekly by treatment with 0.05% Trypsin and 0.02% EDTA (Gibco ± BRL, Grand Island, NY, USA).
Reagents and antibodies
Human OSM was purchased from R&D Systems (Minneapolis, MN, USA) and Sigma (Sydney, Australia). Human EGF was purchased from Sigma, while Heregulin (HRG, b2 isoform) was a kind gift of Dr R Fiddes (The Garvan Institute of Medical Research, Sydney, Australia). Human IGF-1, PDGF and SCF were purchased from R&D Systems. FITC-conjugated monoclonal mouse anti-human EMA antibody was purchased from DAKO (Sydney, Australia). FITCconjugated mouse anti-human IgG 2a (isotype control antibody) was a gift from The Monoclonal Antibody Laboratory, The Walter and Eliza Hall Institute of Medical Research (Melbourne, Australia). Rabbit polyclonal antigp130 antibody, M-20, was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal anti-gp130 antibody, B-T6, was a kind gift from John Wijdenes (Diaclone, BesancË on, France). Mouse monoclonal anti EGFR, ErbB-2 and ErbB-3 antibodies were purchased from Neomarkers (Union City, CA, USA) and Calbiochem (Cambridge, MS, USA). Anti-STAT3 antibodies were purchased from Transduction Laboratories (Lexington, KY, USA). Anti phospho-STAT3 antibodies and anti-phosphotyrosine antibodies (4G10) were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Anti-p42/44 and anti-phospho p42/44 antibodies and PD98059 were purchased from New England Biolabs (Beverly, MS, USA). SB203580 was purchased from Calbiochem.
Cell culture assays
Cell proliferation was measured in monolayer culture in 24 well plates. Cells were plated at an initial density of 10 4 cells/ well and cultured in 500 ml RPMI/10% BCS. All experiments were performed in triplicate. Growth factors were added in the exponential phase of cell growth as indicated (OSM 10 ng/ml; EGF 10 ng/ml; HRG 10 ng/ml, PDGF 1 ng/ml, IGF-1 10 ng/ml, SCF 100 ng/ml). The MAPK inhibitor, PD98059 was used in a ®nal concentration of DMSO 50.1%. Cultures were maintained at 378C in a humidi®ed atmosphere containing 10% CO 2 in air. At given time points cells were harvested and counted using a hemocytometer and a light microscope. Cell viability was assessed using eosin exclusion. Clonogenic potential of cells was assessed in a semi-solid culture medium. Cells (200 per ml) were cultured in 35 mm Petri dishes containing 1 ml AIMDM supplemented with 25% BCS, 0.3% (w/v) agar with ®nal concentration of growth factors as outlined above. Cultures were maintained at 378C in a humidi®ed incubator with 5% CO 2 in air. After 14 days, colonies were enumerated using a dissection microscope. A colony was de®ned as a clone of greater than 40 cells. All cultures were performed in triplicate. Statistical analysis of data was performed using the Student's t-test.
Flow cytometry
Cell cycle analysis was performed as previously described (Douglas et al., 1998) . For analysis of cell surface antigens, 10 6 MCF-7 cells were plated into 80 cm 3¯a sks in 10 ml RPMI/10% BCS containing each growth factor as described above. After 7 days, cells were harvested with 10 mM EDTA and resuspended in PBS containing 2% BCS. Approximately 10 5 cells were aliquoted into 5 ml tubes. Cells were washed in PBS/2% BCS, centrifuged (1500 r.p.m., 5 min) and resuspended in 50 ml PBS/2% BCS. Cells were incubated on ice for 20 min with FITC-conjugated EMA or the isotype control antibody (DAKO). All cells were washed in PBS/ 2% BCS and resuspended in 200 ml 0.5 mg/ml propidium iodide (PI). Dead cells, which stained positive with PI, were excluded from further analysis by gating. Cells were analysed using a FACScan¯ow cytometer using the manufacturer's software (LYSIS II, Becton Dickinson, Franklin Lakes, NJ, USA). Each histogram contained a minimum of 10 000 events.
Northern blot analysis
RNA extraction and Northern analysis were performed as previously described (Douglas et al., 1998) . MCF-7 cells were treated with OSM 10 ng/ml and/or EGF 10 ng/ml and harvested at various time points prior to RNA extraction. mRNA expression was determined using cDNA probes complementary to c-fos, c-myc, EGFR and ER as previously described (Douglas et al., 1998) . mRNA of the following sizes was obtained: c-fos, approximately 2 kb; c-myc, approximately 2 kb; EGFR, 10.5 and 5.8 kb; ER, 6.5 kb. The equivalence of mRNA loading was estimated by hybridizing membranes with a 1.3 kb cDNA complementary to GAPDH. All experiments were performed on at least two independent mRNA samples.
Morphological analysis
Cells were plated in¯askettes at a density of 5610 4 cells/ ask in 2 ml RPMI/10% BCS with or without the appropriate growth factor(s). After 7 days, chambers were removed and slides washed and ®xed in May ± Grunwald ± Giemsa. For study of ER expression cells were ®xed in 95% ethanol and then stained using an anti-ER antibody. To visualize neutral lipids, slides were washed in PBS, air dried and stained with the lipid staining dye, Oil-Red-O.
Immunoprecipitation and Western blot analysis
MCF-7 or MDA-MB-231 cells were seeded in 150 mm 3 plates and grown until con¯uent. Cells were starved of serum overnight. Following this, fresh serum-free medium was added, with or without growth factor as speci®ed (OSM 50 ng/ml; EGF 10 ng/ml), in the presence of sodium orthovanadate (Na 3 VO 4 ) 1 mM and sodium¯uoride (NaF) 1 mM (Sigma). Cells were incubated at 378C in the presence of growth factor for 15 min or at time points otherwise indicated and then harvested with 10 mM EDTA. Whole-cell lysates were prepared using an ice cold lysis buer (1% Triton-X-100, 50 mM Tris HCl, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 mM Na 3 VO 4 ), containing one complete protease inhibitor tablet (Boehringer Mannheim, Mannheim, Germany) per 50 ml of lysis buer. Lysates were precleared using protein G sepharose and IgG (Amersham Pharmacia, Sydney, Australia). Lysates were immunoprecipitated at 48C with the indicated antibody. All experiments were performed with the inclusion of negative controls where equal amounts of lysate were immunoprecipitated with an irrelevant, isotype matched antibody. M1/UR21 cells transfected with human gp130 were used as an additional negative control for gp130/ ErbB-2 co-immunoprecipitation experiments. Immunoprecipitates were collected using protein G sepharose beads. Reducing sample buer was added to each immunoprecipitate and samples were boiled for 5 min prior to electrophoresis on 8 or 10% polyacrylamide gels. Equal concentrations of immunoprecipitates or whole cell lysates (100 mg) were electrophoresed at 150 V for 1 ± 1.5 h. Gels were transferred onto a PVDF membrane for 2 h at 250 mA. Membranes were washed in PBS containing 0.1% Tween-20 (ICN, Costa Mesa, CA, USA) and blocked overnight in PBS/0.1% w/v Tween containing 5% skim milk powder. Membranes were washed and incubated with primary antibody for 2 h. Following additional washes, membranes were incubated with the secondary antibody (1/3000 anti-mouse, anti-rabbit or anti-sheep horseradish peroxidase) (Amersham Pharmacia) for 1 h. Membranes were washed several times in PBS/0.1% Tween-20, incubated with enhanced chemiluminescence (ECL) reagents (Amersham Pharmacia) and exposed to Kodak-X-Omat ®lm for up to 30 min.
